Impact of Sugammadex Versus Neostigmine/Glycopyrrolate on Perioperative Efficiency

Niaz Deyhim, Amanda Beck, Jonathan Balk, Michael G Liebl, Niaz Deyhim, Amanda Beck, Jonathan Balk, Michael G Liebl

Abstract

Purpose: Neuromuscular blockade in the operating room necessitates the utilization of reversal agents to accelerate postoperative recovery and sustain operating room patient throughput. Cholinesterase inhibitors represent the historical standard of care for neuromuscular blockade reversal within anesthesia practice. Sugammadex, a synthetic gamma-cyclodextrin, was introduced to the market with evidence of more rapid and predictable reversal of neuromuscular blockade compared to alternative agents. Higher medication acquisition costs have limited more extensive use of sugammadex compared to that of neostigmine/glycopyrrolate. The purpose of this study was to examine the impact of sugammadex versus neostigmine/glycopyrrolate on perioperative efficiency to validate medication acquisition cost value.

Methods: A retrospective investigation was performed of patients with a surgical procedure at Houston Methodist Hospital from July 31, 2017 through August 1, 2018. The primary endpoint was time from reversal medication administration to operating room exit. Patient-specific doses were assessed to calculate average medication acquisition costs. The economic benefits of sugammadex were measured through review of average operating room and postanesthesia care unit costs per minute.

Results: There were a total of 640 surgical cases at Houston Methodist Hospital eligible for inclusion into the research study. The time from medication administration to operating room exit was significantly faster for sugammadex compared to neostigmine/glycopyrrolate (P<0.001) upon univariate analysis. However, when measured with linear regression, the difference in operating room exit time between sugammadex and neostigmine/glycopyrrolate was no longer statistically significant (P=0.122). Medication acquisition cost review highlighted a difference of $178.20, favoring use of neostigmine/glycopyrrolate.

Conclusion: The utilization of sugammadex does not correlate to consequential time saved in the operating room or extrapolation to workflow capacity for increased surgical case volume. Consideration of the medication acquisition cost promotes more restrictive use of sugammadex to indications with clinical relevance.

Keywords: anesthesia; neuromuscular blockade; pharmacoeconomics; reversal.

Conflict of interest statement

The authors have declared no potential conflicts of interest. Funding was not received for this research study.

© 2020 Deyhim et al.

References

    1. Carron M, Zarantonello F, Lazzarotto N, Tellaroli P, Ori C. Role of sugammadex in accelerating postoperative discharge: a meta-analysis. J Clin Anesth. 2017;39:38–44. doi:10.1016/j.jclinane.2017.03.004
    1. Paton F, Paulden M, Chambers D, et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010;105(5):558–567. doi:10.1093/bja/aeq269
    1. Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015;115(5):743–751. doi:10.1093/bja/aev104
    1. De Robertis E, Zito Marinosci G, Marco Romano G, et al. The use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impact. Clinicoecon Outcomes Res. 2016;8:317–322. doi:10.2147/CEOR.S109951
    1. Hristovska A, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8(8):CD012763.
    1. Watts R, London J, van Wijk R, Lui Y. The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital. Anaesth Intensive Care. 2012;40(2):333–339. doi:10.1177/0310057X1204000218
    1. Carron M, Baratto F, Zarantonello F, Ori C. Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center. Clinicoecon Outcomes Res. 2016;8:43–52. doi:10.2147/CEOR.S100921
    1. Chambers D, Paulden M, Paton F, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess (Rockv). 2010;14(39):1–211.
    1. Sokolovic E, Biro P, Wyss P, et al. Impact of the reduction of anaesthesia turnover time on operating room efficiency. Eur J Anaesthesiol. 2002;19(8):560. doi:10.1097/00003643-200208000-00003
    1. Dexter F, Abouleish A, Epstein R, Whitten C, Lubarsky D. Use of operating room information system data to predict the impact of reducing turnover times on staffing costs. Anesth Analg. 2003;97(4):1119–1126. doi:10.1213/01.ANE.0000082520.68800.79
    1. Zaouter C, Mion S, Palomba A, Hemmerling T. A short update on sugammadex with a special focus on economic assessment of its use in North America. J Anesth Clin Res. 2017;8(7):740. doi:10.4172/2155-6148
    1. Ledowski T, Hillyard S, Kozman A, et al. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intensive Care. 2012;40(2):340–343. doi:10.1177/0310057X1204000219
    1. Jones R, Caldwell J, Brull S, Soto R. Reversal of profound rocuronium-induced blockade with sugammadex. Anesthesiology. 2008;109(5):816–824. doi:10.1097/ALN.0b013e31818a3fee
    1. Khuenl-Brady K, Wattwil M, Vanacker B, Lora-Tamayo J, Rietbergen H, Álvarez-Gómez J. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010;110(1):64–73. doi:10.1213/ane.0b013e3181ac53c3
    1. Chazot T, Dumont G, Le Guen M, Hausser-Hauw C, Liu N, Fischler M. Sugammadex administration results in arousal from intravenous anaesthesia: a clinical and electroencephalographic observation. Br J Anaesth. 2011;106(6):914–916. doi:10.1093/bja/aer142
    1. Illman H, Antila H, Olkkola K. Reversal of neuromuscular blockade by sugammadex does not affect EEG derived indices of depth of anesthesia. J Clin Monit Comput. 2010;24(5):371–376. doi:10.1007/s10877-010-9257-x
    1. Copp M, Barrett T. Sugammadex: role in current anaesthetic practice and its safety benefits for patients. World J Anesthesiol. 2015;4(3):66. doi:10.5313/wja.v4.i3.66
    1. Lemmens HJ, El-Orbany MI, Berry J, Morte JB Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010;10(1):15. doi:10.1186/1471-2253-10-15
    1. Bensghir M, Elkoundi A, Ahtil R, Meziane M, Haimeur C. Use of sugammadex in parotid surgery: a case report. J Med Case Rep. 2016;10(1):187. doi:10.1186/s13256-016-0972-x
    1. Kopman A, Naguib M. Laparoscopic surgery and muscle relaxants. Anesth Analg. 2015;120(1):51–58. doi:10.1213/ANE.0000000000000471
    1. Ünal DY, Baran İ, Mutlu M, Ural G, Akkaya T, Özlü O. Comparison of sugammadex versus neostigmine costs and respiratory complications in patients with obstructive sleep apnoea. Turk J Anaesthesiol Reanim. 2015;43(6):387–395. doi:10.5152/TJAR.2015.35682
    1. Amao R, Zornow M, Cowan R, Cheng D, Morte J, Allard M. Use of sugammadex in patients with a history of pulmonary disease. J Clin Anesth. 2012;24(4):289–297. doi:10.1016/j.jclinane.2011.09.006
    1. Dahl V, Pendeville P, Hollmann M, Heier T, Abels E, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26(10):874–884. doi:10.1097/EJA.0b013e32832c605b
    1. McDonagh D, Benedict P, Kovac A, et al. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. Anesthesiology. 2011;114(2):318–329. doi:10.1097/ALN.0b013e3182065c36
    1. Leonard M, Thyagarajan R, Wilson A, Sekeres M. Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee. Am J Health Sys Pharm. 2018;75(7):451–455. doi:10.2146/ajhp170531
    1. Abramowitz P. Controlling financial variables—changing prescribing patterns. Am J Health Sys Pharm. 1984;41(3):503–515. doi:10.1093/ajhp/41.3.503

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe